1993]. However, G-CSF has rarely been used to continue clozapine treatment in patients with neutropenia, as evidenced by the scant literature [Dunk, 2006; Chin-Yee et al. 1996; Conus et al. 2001; Sperner-unterweger et al. 1998; Majczenko and Stewart, 2008; Rajagopal et al. 2007; Joffe et al. 2009, Hagg et al. 2003; Mathewson and Lindenmayer, 2007]. Inhibitors,research,lifescience,medical None of the patients described in this literature experienced significant side effects associated

with G-CSF. Aims None of the patients described in the above case reports were in a secure psychiatric setting. We aim to describe the treatment of three patients with clozapine and G-CSF in a secure psychiatric hospital in the UK. All of the patients had previously developed neutropenia that was associated with clozapine treatment. For the purpose of this small case Inhibitors,research,lifescience,medical series the authors included patients who have ‘treatment-resistant’ schizophrenia, who had previously received clozapine

and developed neutropenia associated with this treatment. Inhibitors,research,lifescience,medical All of the patients have a significant history of violence. Method Clinical data were collected from reviewing inpatient notes. Data were also obtained from pharmacy records, pertaining to prescription and administration of selleck chemical medications, and from the security department. All incident reports (incidents of aggression and violence are recorded within the hospital in a standardized way) were Inhibitors,research,lifescience,medical reviewed for each patient. For the purpose of anonymity some of the irrelevant details have been altered. Because the use of G-CSF as a treatment for clozapine-related neutropenia is not a licensed indication, the authors were careful to follow a process of discussion and consultation prior to implementing this novel treatment regime. The plans were discussed

and formulated with the patients’ multidisciplinary care teams and then discussed with the patients themselves. If possible, informed consent was obtained from the patients. When this was not feasible, a discussion of best interests Inhibitors,research,lifescience,medical included the views and opinions of patients’ families and carers. In the latter case the view of a second opinion appointed doctor was also sought, in line with the provisions of the Mental Health Act. All patients were formally detained under the Act. In the interests of peer review, and because of the use of a nontrust formulary treatment, the opinion of the appropriate Thymidine kinase clinical director was sought and agreement obtained prior to commencing the trial. In addition, the case histories were presented for further peer review at local academic meetings. Owing to the specialist nature of the proposed intervention, the opinion and involvement of a haematologist was sought at an early stage. This involvement was essential in terms of excluding other specific, treatable causes of neutropenia as well as advising on the technical use of G-CSF.